Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Phase III MANEUVER trial ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA, Darmstadt, Germany collaborations. The ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

European Research Program with Eleven Institutions from Six Countries In 2023, Merck KGaA, Darmstadt, Germany and Intel announced the joint investment in the academic research program for a period ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...